Incyte Corporation vs MPLX LP — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while MPLX LP trades at $56.75 (market cap $57.97B). The key difference: MPLX LP is far larger — about 2.5× Incyte Corporation's market cap, and MPLX LP pays a 7.54% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MPLX | |
|---|---|---|
Market Cap | $23.11B | $57.97B |
Sector | Health | Technology |
52-Week High | $118.52 | $59.17 |
52-Week Low | $67.38 | $47.80 |
Enterprise Value | $19.13B | $82.60B |
Dividend Yield | — | 7.54% |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →